3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
41
Carcinoma, Non-Small-Cell Lung
28
Lung Neoplasms
8
Triple Negative Breast Neoplasms
6
Neoplasm Metastasis
6
Neoplasms
5
Uterine Cervical Neoplasms
4
Recurrence
2
Mesothelioma
2
Lymphoma, Non-Hodgkin
2
Carcinoma
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Thoracic Neoplasms
1
Stomach Neoplasms
1
Sarcoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Ovarian Neoplasms
1
Nonhematologic Malignancies
1
Non-Squamous Non-Small Cell Lung Cancer
1
Non - Small Cell Lung Cancer NSCLC
1
Neuroendocrine Tumors
1
NSCLC
1
Metatropic dwarfism
1
Metastatic HER2-positive Breast Cancer
1
Lung Diseases
1
Lethal Congenital Contracture Syndrome 2
1
HR+HER2- Breast Cancer
1
HER2-positive Advanced Breast Cancer
1
Desmoplastic Small Round Cell Tumor
1
Interventions
Vinorelbine
1
Temozolomide
1
Radiotherapy
1
Genz-644282
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Metatropic dwarfism
×
Vinorelbine
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts